Since ACE inhibitors prevent kinin degradation in the coronary and renal circulation, it could be through advanced pathways that kinins stimulate NO and PGI2 (important inhibitors of platelet aggregation) to block platelet aggregation, coronary arterial stenosis and eventually myocardial infarction or renal ischemia. The gene discussed is ACE; the disease is myocardial infarction.